NGM Biopharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

NGM Biopharmaceuticals

02/11/2023 22:13

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -59 cents.  The mean expectation of
six analysts for the quarter was for a loss of 42 cents per
share. Wall Street expected results to range from -48 cents
to -33 cents per share.
    * Revenue fell 92.6% to $582.00 thousand from a year ago;
analysts
expected $2.46 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The company reported a quarterly loss of $28.8 million.
    * NGM Biopharmaceuticals Inc shares had fallen by 27.5% this
quarter and lost 84.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $6.00 
This summary was machine generated from LSEG data November 2 at
10:12 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.42          -0.35          Beat
 Jun. 30 2023      -0.50          -0.46          Beat
 Mar. 31 2023      -0.52          -0.58          Missed
 Dec. 31 2022      -0.51          -0.45          Beat